Loading…
Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) Methods In this multi-institutional cohort, preoperative blood-based SII was retrospectively as...
Saved in:
Published in: | World journal of urology 2021-12, Vol.39 (12), p.4355-4361 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23 |
---|---|
cites | cdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23 |
container_end_page | 4361 |
container_issue | 12 |
container_start_page | 4355 |
container_title | World journal of urology |
container_volume | 39 |
creator | Katayama, Satoshi Mori, Keiichiro Pradere, Benjamin Laukhtina, Ekaterina Schuettfort, Victor M. Quhal, Fahad Motlagh, Reza Sari Mostafaei, Hadi Grossmann, Nico C. Rajwa, Pawel Moschini, Marco Mathieu, Romain Abufaraj, Mohammad D’Andrea, David Compérat, Eva Haydter, Martin Egawa, Shin Nasu, Yasutomo Shariat, Shahrokh F. |
description | Purpose
We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC)
Methods
In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.
Results
Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77;
P
= 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48;
P
= 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31;
P
= 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3;
P
= 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.
Conclusion
Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC. |
doi_str_mv | 10.1007/s00345-021-03740-3 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2543445012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhD3BAkbjAwTD-ip0LUlUBRVoJDnA23mSy6yqxi51E7b_HS0qBHrjY8swz74znJeQ5gzcMQL_NAEIqCpxREFoCFQ_IhkkhqNG8fkg2oLmksjHihDzJ-RKA6RrUY3IiZMG4kRvy_UuK-xDz5NtqccOMVeyr6YBVvskTjiXqx3EOSH3oBzeObvIxVD50eF3OKsRAxzm3A5bX4rJfsNoNruswVa0LLaan5FHvhozPbu9T8u3D-6_nF3T7-eOn87MtbRWYiSpQyE1tHKubRrfIOscaw1rcdU3NEfqml6wTqtG1Ukah0VIXuOl4j9jtuDgl71bdq3k3YtdimJIb7FXyo0s3Njpv_80Ef7D7uFhTlwVqWQRerwKHe2UXZ1t7jEHZmOIACyvsq9tmKf6YMU929LnFYXAB45wtV1JIqYAd53p5D72McwplFYVqjBFKgC4UX6k2xZwT9ncTMLBHs-1qti2z2l9mW1GKXvz95buS3-4WQKxALqmwx_Sn939kfwIyoLUt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598835307</pqid></control><display><type>article</type><title>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</title><source>Springer Nature</source><creator>Katayama, Satoshi ; Mori, Keiichiro ; Pradere, Benjamin ; Laukhtina, Ekaterina ; Schuettfort, Victor M. ; Quhal, Fahad ; Motlagh, Reza Sari ; Mostafaei, Hadi ; Grossmann, Nico C. ; Rajwa, Pawel ; Moschini, Marco ; Mathieu, Romain ; Abufaraj, Mohammad ; D’Andrea, David ; Compérat, Eva ; Haydter, Martin ; Egawa, Shin ; Nasu, Yasutomo ; Shariat, Shahrokh F.</creator><creatorcontrib>Katayama, Satoshi ; Mori, Keiichiro ; Pradere, Benjamin ; Laukhtina, Ekaterina ; Schuettfort, Victor M. ; Quhal, Fahad ; Motlagh, Reza Sari ; Mostafaei, Hadi ; Grossmann, Nico C. ; Rajwa, Pawel ; Moschini, Marco ; Mathieu, Romain ; Abufaraj, Mohammad ; D’Andrea, David ; Compérat, Eva ; Haydter, Martin ; Egawa, Shin ; Nasu, Yasutomo ; Shariat, Shahrokh F. ; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU) ; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><description>Purpose
We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC)
Methods
In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.
Results
Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77;
P
= 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48;
P
= 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31;
P
= 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3;
P
= 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.
Conclusion
Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-021-03740-3</identifier><identifier>PMID: 34143284</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Bladder cancer ; Cancer ; Decision making ; Female ; Humans ; Inflammation ; Inflammation - etiology ; Invasiveness ; Life Sciences ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Invasiveness ; Nephrology ; Oncology ; Original ; Original Article ; Patients ; Prediction models ; Prognosis ; Retrospective Studies ; Risk Assessment ; Urinary Bladder Neoplasms - complications ; Urinary Bladder Neoplasms - immunology ; Urinary Bladder Neoplasms - pathology ; Urology</subject><ispartof>World journal of urology, 2021-12, Vol.39 (12), p.4355-4361</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</citedby><cites>FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</cites><orcidid>0000-0002-8377-2457 ; 0000-0002-6603-6319 ; 0000-0002-8163-6953 ; 0000-0002-6147-6569 ; 0000-0002-8953-0272</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34143284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03285200$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Katayama, Satoshi</creatorcontrib><creatorcontrib>Mori, Keiichiro</creatorcontrib><creatorcontrib>Pradere, Benjamin</creatorcontrib><creatorcontrib>Laukhtina, Ekaterina</creatorcontrib><creatorcontrib>Schuettfort, Victor M.</creatorcontrib><creatorcontrib>Quhal, Fahad</creatorcontrib><creatorcontrib>Motlagh, Reza Sari</creatorcontrib><creatorcontrib>Mostafaei, Hadi</creatorcontrib><creatorcontrib>Grossmann, Nico C.</creatorcontrib><creatorcontrib>Rajwa, Pawel</creatorcontrib><creatorcontrib>Moschini, Marco</creatorcontrib><creatorcontrib>Mathieu, Romain</creatorcontrib><creatorcontrib>Abufaraj, Mohammad</creatorcontrib><creatorcontrib>D’Andrea, David</creatorcontrib><creatorcontrib>Compérat, Eva</creatorcontrib><creatorcontrib>Haydter, Martin</creatorcontrib><creatorcontrib>Egawa, Shin</creatorcontrib><creatorcontrib>Nasu, Yasutomo</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><title>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Purpose
We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC)
Methods
In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.
Results
Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77;
P
= 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48;
P
= 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31;
P
= 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3;
P
= 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.
Conclusion
Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.</description><subject>Aged</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Decision making</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - etiology</subject><subject>Invasiveness</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prediction models</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Urinary Bladder Neoplasms - complications</subject><subject>Urinary Bladder Neoplasms - immunology</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urology</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhi0EokvhD3BAkbjAwTD-ip0LUlUBRVoJDnA23mSy6yqxi51E7b_HS0qBHrjY8swz74znJeQ5gzcMQL_NAEIqCpxREFoCFQ_IhkkhqNG8fkg2oLmksjHihDzJ-RKA6RrUY3IiZMG4kRvy_UuK-xDz5NtqccOMVeyr6YBVvskTjiXqx3EOSH3oBzeObvIxVD50eF3OKsRAxzm3A5bX4rJfsNoNruswVa0LLaan5FHvhozPbu9T8u3D-6_nF3T7-eOn87MtbRWYiSpQyE1tHKubRrfIOscaw1rcdU3NEfqml6wTqtG1Ukah0VIXuOl4j9jtuDgl71bdq3k3YtdimJIb7FXyo0s3Njpv_80Ef7D7uFhTlwVqWQRerwKHe2UXZ1t7jEHZmOIACyvsq9tmKf6YMU929LnFYXAB45wtV1JIqYAd53p5D72McwplFYVqjBFKgC4UX6k2xZwT9ncTMLBHs-1qti2z2l9mW1GKXvz95buS3-4WQKxALqmwx_Sn939kfwIyoLUt</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Katayama, Satoshi</creator><creator>Mori, Keiichiro</creator><creator>Pradere, Benjamin</creator><creator>Laukhtina, Ekaterina</creator><creator>Schuettfort, Victor M.</creator><creator>Quhal, Fahad</creator><creator>Motlagh, Reza Sari</creator><creator>Mostafaei, Hadi</creator><creator>Grossmann, Nico C.</creator><creator>Rajwa, Pawel</creator><creator>Moschini, Marco</creator><creator>Mathieu, Romain</creator><creator>Abufaraj, Mohammad</creator><creator>D’Andrea, David</creator><creator>Compérat, Eva</creator><creator>Haydter, Martin</creator><creator>Egawa, Shin</creator><creator>Nasu, Yasutomo</creator><creator>Shariat, Shahrokh F.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8377-2457</orcidid><orcidid>https://orcid.org/0000-0002-6603-6319</orcidid><orcidid>https://orcid.org/0000-0002-8163-6953</orcidid><orcidid>https://orcid.org/0000-0002-6147-6569</orcidid><orcidid>https://orcid.org/0000-0002-8953-0272</orcidid></search><sort><creationdate>20211201</creationdate><title>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</title><author>Katayama, Satoshi ; Mori, Keiichiro ; Pradere, Benjamin ; Laukhtina, Ekaterina ; Schuettfort, Victor M. ; Quhal, Fahad ; Motlagh, Reza Sari ; Mostafaei, Hadi ; Grossmann, Nico C. ; Rajwa, Pawel ; Moschini, Marco ; Mathieu, Romain ; Abufaraj, Mohammad ; D’Andrea, David ; Compérat, Eva ; Haydter, Martin ; Egawa, Shin ; Nasu, Yasutomo ; Shariat, Shahrokh F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Decision making</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - etiology</topic><topic>Invasiveness</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prediction models</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Urinary Bladder Neoplasms - complications</topic><topic>Urinary Bladder Neoplasms - immunology</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katayama, Satoshi</creatorcontrib><creatorcontrib>Mori, Keiichiro</creatorcontrib><creatorcontrib>Pradere, Benjamin</creatorcontrib><creatorcontrib>Laukhtina, Ekaterina</creatorcontrib><creatorcontrib>Schuettfort, Victor M.</creatorcontrib><creatorcontrib>Quhal, Fahad</creatorcontrib><creatorcontrib>Motlagh, Reza Sari</creatorcontrib><creatorcontrib>Mostafaei, Hadi</creatorcontrib><creatorcontrib>Grossmann, Nico C.</creatorcontrib><creatorcontrib>Rajwa, Pawel</creatorcontrib><creatorcontrib>Moschini, Marco</creatorcontrib><creatorcontrib>Mathieu, Romain</creatorcontrib><creatorcontrib>Abufaraj, Mohammad</creatorcontrib><creatorcontrib>D’Andrea, David</creatorcontrib><creatorcontrib>Compérat, Eva</creatorcontrib><creatorcontrib>Haydter, Martin</creatorcontrib><creatorcontrib>Egawa, Shin</creatorcontrib><creatorcontrib>Nasu, Yasutomo</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katayama, Satoshi</au><au>Mori, Keiichiro</au><au>Pradere, Benjamin</au><au>Laukhtina, Ekaterina</au><au>Schuettfort, Victor M.</au><au>Quhal, Fahad</au><au>Motlagh, Reza Sari</au><au>Mostafaei, Hadi</au><au>Grossmann, Nico C.</au><au>Rajwa, Pawel</au><au>Moschini, Marco</au><au>Mathieu, Romain</au><au>Abufaraj, Mohammad</au><au>D’Andrea, David</au><au>Compérat, Eva</au><au>Haydter, Martin</au><au>Egawa, Shin</au><au>Nasu, Yasutomo</au><au>Shariat, Shahrokh F.</au><aucorp>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</aucorp><aucorp>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>39</volume><issue>12</issue><spage>4355</spage><epage>4361</epage><pages>4355-4361</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Purpose
We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC)
Methods
In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.
Results
Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77;
P
= 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48;
P
= 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31;
P
= 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3;
P
= 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.
Conclusion
Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34143284</pmid><doi>10.1007/s00345-021-03740-3</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8377-2457</orcidid><orcidid>https://orcid.org/0000-0002-6603-6319</orcidid><orcidid>https://orcid.org/0000-0002-8163-6953</orcidid><orcidid>https://orcid.org/0000-0002-6147-6569</orcidid><orcidid>https://orcid.org/0000-0002-8953-0272</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0724-4983 |
ispartof | World journal of urology, 2021-12, Vol.39 (12), p.4355-4361 |
issn | 0724-4983 1433-8726 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602174 |
source | Springer Nature |
subjects | Aged Bladder cancer Cancer Decision making Female Humans Inflammation Inflammation - etiology Invasiveness Life Sciences Male Medicine Medicine & Public Health Middle Aged Neoplasm Invasiveness Nephrology Oncology Original Original Article Patients Prediction models Prognosis Retrospective Studies Risk Assessment Urinary Bladder Neoplasms - complications Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - pathology Urology |
title | Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A28%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20the%20systemic%20immune-inflammation%20index%20in%20non-muscle%20invasive%20bladder%20cancer&rft.jtitle=World%20journal%20of%20urology&rft.au=Katayama,%20Satoshi&rft.aucorp=European%20Association%20of%20Urology%E2%80%93Young%20Academic%20Urologists%20Urothelial%20Carcinoma%20Working%20Group%20(EAU-YAU)&rft.date=2021-12-01&rft.volume=39&rft.issue=12&rft.spage=4355&rft.epage=4361&rft.pages=4355-4361&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-021-03740-3&rft_dat=%3Cproquest_pubme%3E2543445012%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2598835307&rft_id=info:pmid/34143284&rfr_iscdi=true |